Conexeu Sciences (NASDAQ:CNXU) Upgraded to Hold at Zacks Research

Posted by Francis Steltz on Jul 1st, 2026

Zacks Research upgraded shares of Conexeu Sciences (NASDAQ:CNXU – Free Report) to a hold rating in a research note released on Monday,Zacks.com reports.

A number of other research firms also recently issued reports on CNXU. Wall Street Zen raised shares of Conexeu Sciences to a “hold” rating in a report on Saturday, May 30th. HC Wainwright assumed coverage on Conexeu Sciences in a research note on Monday, June 22nd. They issued a “buy” rating and a $20.00 price target for the company. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Check Out Our Latest Research Report on CNXU

Conexeu Sciences Price Performance

Shares of NASDAQ CNXU opened at $10.92 on Monday. Conexeu Sciences has a one year low of $9.60 and a one year high of $18.79.

Conexeu Sciences (NASDAQ:CNXU – Get Free Report) last announced its earnings results on Monday, June 15th. The company reported ($0.11) earnings per share (EPS) for the quarter.

Insider Transactions at Conexeu Sciences

In other news, Director Lynn Sebastian Purcell acquired 202,500 shares of the stock in a transaction on Thursday, June 18th. The stock was acquired at an average cost of $0.80 per share, for a total transaction of $162,000.00. Following the completion of the transaction, the director directly owned 2,734,240 shares in the company, valued at approximately $2,187,392. This trade represents a 8.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Conexeu Sciences News Roundup

Here are the key news stories impacting Conexeu Sciences this week:

Positive Sentiment: HC Wainwright maintained a Buy rating and $20 price target, signaling confidence in Conexeu Sciences despite near-term losses. Conexeu Sciences Free Report
Positive Sentiment: The firm’s longer-term estimates turn sharply positive, with projected EPS of $1.02 for FY2028, $1.70 for FY2029, and $2.52 for FY2030, suggesting potential future earnings growth. Conexeu Sciences Free Report
Neutral Sentiment: HC Wainwright’s near-term forecasts remain negative, including estimated losses of ($0.40) per share for FY2026 and ($0.53) for FY2027, which keeps investors focused on execution rather than current profitability. Conexeu Sciences Free Report

Conexeu Sciences Company Profile

(Get Free Report)

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory.